- Home
- NEXN vs TRVI Comparison
NEXN vs TRVI Comparison
Compare NEXN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXN
- TRVI
- Stock Information
- Founded
- NEXN 2007
- TRVI 2011
- Country
- NEXN Israel
- TRVI United States
- Employees
- NEXN N/A
- TRVI N/A
- Industry
- NEXN Computer Software: Programming Data Processing
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NEXN Technology
- TRVI Health Care
- Exchange
- NEXN Nasdaq
- TRVI Nasdaq
- Market Cap
- NEXN 736.9M
- TRVI 629.8M
- IPO Year
- NEXN 2021
- TRVI 2019
- Fundamental
- Price
- NEXN $11.62
- TRVI $6.51
- Analyst Decision
- NEXN Strong Buy
- TRVI Strong Buy
- Analyst Count
- NEXN 10
- TRVI 8
- Target Price
- NEXN $13.22
- TRVI $19.31
- AVG Volume (30 Days)
- NEXN 464.0K
- TRVI 1.0M
- Earning Date
- NEXN 05-14-2025
- TRVI 05-08-2025
- Dividend Yield
- NEXN N/A
- TRVI N/A
- EPS Growth
- NEXN N/A
- TRVI N/A
- EPS
- NEXN 0.65
- TRVI N/A
- Revenue
- NEXN $369,375,000.00
- TRVI N/A
- Revenue This Year
- NEXN $5.43
- TRVI N/A
- Revenue Next Year
- NEXN N/A
- TRVI N/A
- P/E Ratio
- NEXN $17.97
- TRVI N/A
- Revenue Growth
- NEXN 10.36
- TRVI N/A
- 52 Week Low
- NEXN $5.57
- TRVI $2.30
- 52 Week High
- NEXN $12.60
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- NEXN 60.97
- TRVI 54.36
- Support Level
- NEXN $10.60
- TRVI $6.08
- Resistance Level
- NEXN $12.00
- TRVI $6.47
- Average True Range (ATR)
- NEXN 0.58
- TRVI 0.34
- MACD
- NEXN -0.07
- TRVI -0.02
- Stochastic Oscillator
- NEXN 51.00
- TRVI 67.01
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.